Health
FDA authorizes fingerstick COVID-19 antibody test – Mass Device
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Palo Alto, Calif-based Nirmidas Biotech’s MidaSpot rapid COVID-19 antibody combo detection kit uses fingerstick serology testing to detect IgG/IgM antibodies related to the SARS-CoV-2 virus causing COVID-19, according to a news release.
MidaSpot, touted by Nirmidas as the first point-of-care fingerstick COVID-19 test to receive EUA, can now be administered…
-
General20 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General17 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
Noosa News23 hours agoDance Nation shows the messy truth of adolescent dance comps
-
General22 hours agoCollingwood’s Sarah Rowe returned after just 16 days from collarbone surgery as Magpies beat GWS in AFLW